top of page

NCI-2020-07076

A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors


Antibodies are part of our body's defense system. They can specifically recognize damaging substances in the body, including tumor cells. The drug SFR338 is a new immune therapy drug that works with the body’s immune system, turning it on and fighting tumors from growing. This clinical trial will study the effects and benefits of the drug SRF388, when given by itself or combined with other types of medicine, in patients with solid tumors like hepatocellular carcinoma (liver cancer).


For more information about the trial, click the link below:

NCI-2020-07076

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064

NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a tumor that is “resectable,” which means that it is able to be rem

NCI-2022-05056

Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with ot

bottom of page